- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Artificial Intelligence and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
David J. Farber
News 13 results
In the News · Source: Verywell Health
July 14, 2023
David Farber discusses the FDA recently granting full approval to Leqembi, a drug to treat mild Alzheimer’s disease
Recognition
June 8, 2023
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2023 Guide
In the News · Source: Drug Channels
December 12, 2022
David Farber, Preeya Pinto, John Shakow, Eva Temkin and Christine Carletta’s client alert is referenced in a profile on the Inflation Reduction Act of 2022
Events 18 results
Conference
November 7, 2023
Pharmaceutical University 2023
Conference
November 1, 2022
Pharmaceutical University 2022
Webinar
August 18, 2022
An Analysis of the Prescription Drug Pricing Provisions of the Inflation Reduction Act of 2022
Speaking Engagement
April 12, 2022
David Farber, Lisa Dwyer, Adam Solander to Speak at BioDesign Israel Program
Insights 104 results
Client Alert
October 3, 2023
FDA's Latest Salvo in the LDT Wars
Client Alert
July 12, 2023
A Pathway for Medicare Coverage for Breakthrough Devices: Take Two
Article · Source: Alliance for Aging Research
February 13, 2023
Facade of Evidence: How Medicare's Coverage with Evidence Development Paradigm Rations Care and Exacerbates Inequity
Client Alert
August 15, 2022
Price Negotiation, Medicare Rebates, and Benefit Reform